Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 129 entries
Sorted by: Best Match Show Resources per page
S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Eigentler TK, Mühlenbein C, Follmann M, Schadendorf D, Garbe C.
PMID: 28591444
J Dtsch Dermatol Ges. 2017 Jun;15(6):e1-e41. doi: 10.1111/ddg.13247.

No abstract available.

Cite
Eigentler TK, Mühlenbein C, Follmann M, et al. S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0. J Dtsch Dermatol Ges. 2017;15(6):e1-e41doi: 10.1111/ddg.13247.
Eigentler, T. K., Mühlenbein, C., Follmann, M., Schadendorf, D., & Garbe, C. (2017). S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 15(6), e1-e41. https://doi.org/10.1111/ddg.13247
Eigentler, Thomas K, et al. "S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0." Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG vol. 15,6 (2017): e1-e41. doi: https://doi.org/10.1111/ddg.13247
Eigentler TK, Mühlenbein C, Follmann M, Schadendorf D, Garbe C. S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0. J Dtsch Dermatol Ges. 2017 Jun;15(6):e1-e41. doi: 10.1111/ddg.13247. PMID: 28591444.
Copy Download .nbib Format: NLM
The impact of the immune system on tumor: angiogenesis and vascular remodeling.

Frontiers in oncology

Stockmann C, Schadendorf D, Klose R, Helfrich I.
PMID: 24782982
Front Oncol. 2014 Apr 08;4:69. doi: 10.3389/fonc.2014.00069. eCollection 2014.

Angiogenesis, the formation of new blood vessels, as well as inflammation with massive infiltration of leukocytes are hallmarks of various tumor entities. Various epidemiological, clinical, and experimental studies have not only demonstrated a link between chronic inflammation and cancer...

Cite
Stockmann C, Schadendorf D, Klose R, et al. The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol. 2014;4:69doi: 10.3389/fonc.2014.00069.
Stockmann, C., Schadendorf, D., Klose, R., & Helfrich, I. (2014). The impact of the immune system on tumor: angiogenesis and vascular remodeling. Frontiers in oncology, 469. https://doi.org/10.3389/fonc.2014.00069
Stockmann, Christian, et al. "The impact of the immune system on tumor: angiogenesis and vascular remodeling." Frontiers in oncology vol. 4 (2014): 69. doi: https://doi.org/10.3389/fonc.2014.00069
Stockmann C, Schadendorf D, Klose R, Helfrich I. The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol. 2014 Apr 08;4:69. doi: 10.3389/fonc.2014.00069. eCollection 2014. PMID: 24782982; PMCID: PMC3986554.
Copy Download .nbib Format: NLM
CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma.

Frontiers in oncology

Löffek S, Ullrich N, Görgens A, Murke F, Eilebrecht M, Menne C, Giebel B, Schadendorf D, Singer BB, Helfrich I.
PMID: 26539411
Front Oncol. 2015 Oct 19;5:234. doi: 10.3389/fonc.2015.00234. eCollection 2015.

Widespread metastasis is the leading course of death in many types of cancer, including malignant melanoma. The process of metastasis can be divided into a number of complex cell biological events, collectively termed the "invasion-metastasis cascade." Previous reports have...

Cite
Löffek S, Ullrich N, Görgens A, et al. CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. Front Oncol. 2015;5:234doi: 10.3389/fonc.2015.00234.
Löffek, S., Ullrich, N., Görgens, A., Murke, F., Eilebrecht, M., Menne, C., Giebel, B., Schadendorf, D., Singer, B. B., & Helfrich, I. (2015). CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. Frontiers in oncology, 5234. https://doi.org/10.3389/fonc.2015.00234
Löffek, Stefanie, et al. "CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma." Frontiers in oncology vol. 5 (2015): 234. doi: https://doi.org/10.3389/fonc.2015.00234
Löffek S, Ullrich N, Görgens A, Murke F, Eilebrecht M, Menne C, Giebel B, Schadendorf D, Singer BB, Helfrich I. CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. Front Oncol. 2015 Oct 19;5:234. doi: 10.3389/fonc.2015.00234. eCollection 2015. PMID: 26539411; PMCID: PMC4609850.
Copy Download .nbib Format: NLM
Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach.

Proteomics. Clinical applications

Matharoo-Ball B, Ratcliffe L, Lancashire L, Ugurel S, Miles AK, Weston DJ, Rees R, Schadendorf D, Ball G, Creaser CS.
PMID: 21136712
Proteomics Clin Appl. 2007 Jun;1(6):605-20. doi: 10.1002/prca.200700022.

The prognosis of advanced metastatic melanoma (American Joint Committee on Cancer (AJCC) stage IV) remains dismal with a 5-year survival rate of 6-18%. In the present study, an integrated MALDI mass spectrometric approach combined with artificial neural networks (ANNs)...

Cite
Matharoo-Ball B, Ratcliffe L, Lancashire L, et al. Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach. Proteomics Clin Appl. 2007;1(6):605-20doi: 10.1002/prca.200700022.
Matharoo-Ball, B., Ratcliffe, L., Lancashire, L., Ugurel, S., Miles, A. K., Weston, D. J., Rees, R., Schadendorf, D., Ball, G., & Creaser, C. S. (2007). Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach. Proteomics. Clinical applications, 1(6), 605-20. https://doi.org/10.1002/prca.200700022
Matharoo-Ball, Balwir, et al. "Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach." Proteomics. Clinical applications vol. 1,6 (2007): 605-20. doi: https://doi.org/10.1002/prca.200700022
Matharoo-Ball B, Ratcliffe L, Lancashire L, Ugurel S, Miles AK, Weston DJ, Rees R, Schadendorf D, Ball G, Creaser CS. Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach. Proteomics Clin Appl. 2007 Jun;1(6):605-20. doi: 10.1002/prca.200700022. PMID: 21136712.
Copy Download .nbib Format: NLM
Evolution of melanoma cross-resistance to CD8.

Oncoimmunology

Pieper N, Zaremba A, Leonardelli S, Harbers FN, Schwamborn M, Lübcke S, Schrörs B, Baingo J, Schramm A, Haferkamp S, Seifert U, Sucker A, Lennerz V, Wölfel T, Schadendorf D, Schilling B, Paschen A, Zhao F.
PMID: 30221038
Oncoimmunology. 2018 Apr 18;7(8):e1450127. doi: 10.1080/2162402X.2018.1450127. eCollection 2018.

The profound but frequently transient clinical responses to BRAF

Cite
Pieper N, Zaremba A, Leonardelli S, et al. Evolution of melanoma cross-resistance to CD8. Oncoimmunology. 2018;7(8):e1450127doi: 10.1080/2162402X.2018.1450127.
Pieper, N., Zaremba, A., Leonardelli, S., Harbers, F. N., Schwamborn, M., Lübcke, S., Schrörs, B., Baingo, J., Schramm, A., Haferkamp, S., Seifert, U., Sucker, A., Lennerz, V., Wölfel, T., Schadendorf, D., Schilling, B., Paschen, A., & Zhao, F. (2018). Evolution of melanoma cross-resistance to CD8. Oncoimmunology, 7(8), e1450127. https://doi.org/10.1080/2162402X.2018.1450127
Pieper, Natalia, et al. "Evolution of melanoma cross-resistance to CD8." Oncoimmunology vol. 7,8 (2018): e1450127. doi: https://doi.org/10.1080/2162402X.2018.1450127
Pieper N, Zaremba A, Leonardelli S, Harbers FN, Schwamborn M, Lübcke S, Schrörs B, Baingo J, Schramm A, Haferkamp S, Seifert U, Sucker A, Lennerz V, Wölfel T, Schadendorf D, Schilling B, Paschen A, Zhao F. Evolution of melanoma cross-resistance to CD8. Oncoimmunology. 2018 Apr 18;7(8):e1450127. doi: 10.1080/2162402X.2018.1450127. eCollection 2018. PMID: 30221038; PMCID: PMC6136878.
Copy Download .nbib Format: NLM
Immunotherapy in non-melanoma skin cancer: updates and new perspectives.

Drugs in context

Ascierto PA, Schadendorf D.
PMID: 30936937
Drugs Context. 2019 Mar 25;8:212583. doi: 10.7573/dic.212583. eCollection 2019.

No abstract available.

Cite
Ascierto PA, Schadendorf D. Immunotherapy in non-melanoma skin cancer: updates and new perspectives. Drugs Context. 2019;8:212583doi: 10.7573/dic.212583.
Ascierto, P. A., & Schadendorf, D. (2019). Immunotherapy in non-melanoma skin cancer: updates and new perspectives. Drugs in context, 8212583. https://doi.org/10.7573/dic.212583
Ascierto, Paolo Antonio, and Schadendorf, Dirk. "Immunotherapy in non-melanoma skin cancer: updates and new perspectives." Drugs in context vol. 8 (2019): 212583. doi: https://doi.org/10.7573/dic.212583
Ascierto PA, Schadendorf D. Immunotherapy in non-melanoma skin cancer: updates and new perspectives. Drugs Context. 2019 Mar 25;8:212583. doi: 10.7573/dic.212583. eCollection 2019. PMID: 30936937; PMCID: PMC6434981.
Copy Download .nbib Format: NLM
ECG Changes in Melanoma Patients Undergoing Cancer Therapy-Data From the ECoR Registry.

Journal of clinical medicine

Pohl J, Mincu RI, Mrotzek SM, Hinrichs L, Michel L, Livingstone E, Zimmer L, Wakili R, Schadendorf D, Rassaf T, Totzeck M.
PMID: 32630003
J Clin Med. 2020 Jun 30;9(7). doi: 10.3390/jcm9072060.

We aimed to evaluate whether therapy with immune checkpoint inhibitors (ICI) leads to changes in electrocardiogram (ECG) parameters in melanoma patients. We retrospectively examined 41 patients (46% women, age 61 ± 12years) with advanced melanoma (stage III/IV) before and...

Cite
Pohl J, Mincu RI, Mrotzek SM, et al. ECG Changes in Melanoma Patients Undergoing Cancer Therapy-Data From the ECoR Registry. J Clin Med. 2020;9(7)doi: 10.3390/jcm9072060.
Pohl, J., Mincu, R. I., Mrotzek, S. M., Hinrichs, L., Michel, L., Livingstone, E., Zimmer, L., Wakili, R., Schadendorf, D., Rassaf, T., & Totzeck, M. (2020). ECG Changes in Melanoma Patients Undergoing Cancer Therapy-Data From the ECoR Registry. Journal of clinical medicine, 9(7), . https://doi.org/10.3390/jcm9072060
Pohl, Julia, et al. "ECG Changes in Melanoma Patients Undergoing Cancer Therapy-Data From the ECoR Registry." Journal of clinical medicine vol. 9,7 (2020). doi: https://doi.org/10.3390/jcm9072060
Pohl J, Mincu RI, Mrotzek SM, Hinrichs L, Michel L, Livingstone E, Zimmer L, Wakili R, Schadendorf D, Rassaf T, Totzeck M. ECG Changes in Melanoma Patients Undergoing Cancer Therapy-Data From the ECoR Registry. J Clin Med. 2020 Jun 30;9(7). doi: 10.3390/jcm9072060. PMID: 32630003; PMCID: PMC7408861.
Copy Download .nbib Format: NLM
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

European journal of cancer (Oxford, England : 1990)

Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM.
PMID: 34952480
Eur J Cancer. 2021 Dec 21;162:22-33. doi: 10.1016/j.ejca.2021.11.022. Epub 2021 Dec 21.

INTRODUCTION: Despite remarkably improved outcomes with immune checkpoint inhibition, many patients with metastatic melanoma will eventually require further therapy. Chemotherapy has limited activity when used first-line but can alter the tumour microenvironment and does improve efficacy when used in...

Cite
Goldinger SM, Buder-Bakhaya K, Lo SN, et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2021;162:22-33doi: 10.1016/j.ejca.2021.11.022.
Goldinger, S. M., Buder-Bakhaya, K., Lo, S. N., Forschner, A., McKean, M., Zimmer, L., Khoo, C., Dummer, R., Eroglu, Z., Buchbinder, E. I., Ascierto, P. A., Gutzmer, R., Rozeman, E. A., Hoeller, C., Johnson, D. B., Gesierich, A., Kölblinger, P., Bennannoune, N., Cohen, J. V., Kähler, K. C., Wilson, M. A., Cebon, J., Atkinson, V., Smith, J. L., Michielin, O., Long, G. V., Hassel, J. C., Weide, B., Haydu, L. E., Schadendorf, D., McArthur, G., Ott, P. A., Blank, C., Robert, C., Sullivan, R., Hauschild, A., Carlino, M. S., Garbe, C., Davies, M. A., & Menzies, A. M. (2021). Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European journal of cancer (Oxford, England : 1990), 16222-33. https://doi.org/10.1016/j.ejca.2021.11.022
Goldinger, Simone M, et al. "Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis." European journal of cancer (Oxford, England : 1990) vol. 162 (2021): 22-33. doi: https://doi.org/10.1016/j.ejca.2021.11.022
Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2021 Dec 21;162:22-33. doi: 10.1016/j.ejca.2021.11.022. Epub 2021 Dec 21. PMID: 34952480.
Copy Download .nbib Format: NLM
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS.
PMID: 34818112
J Clin Oncol. 2021 Nov 24;JCO2102229. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.

PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.PATIENTS AND METHODS: Patients with previously untreated unresectable stage...

Cite
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2021;JCO2102229doi: 10.1200/JCO.21.02229.
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Butler, M. O., Hill, A., Márquez-Rodas, I., Haanen, J. B. A. G., Guidoboni, M., Maio, M., Schöffski, P., Carlino, M. S., Lebbé, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G. V., Bas, T., Ritchings, C., Larkin, J., & Hodi, F. S. (2021). Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2102229. https://doi.org/10.1200/JCO.21.02229
Wolchok, Jedd D, et al. "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2021): JCO2102229. doi: https://doi.org/10.1200/JCO.21.02229
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2021 Nov 24;JCO2102229. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24. PMID: 34818112; PMCID: PMC8718224.
Copy Download .nbib Format: NLM
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy.

European heart journal

Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, Spomer A, Odersky A, Rischpler C, Herrmann K, Umutlu L, Coman C, Ahrends R, Sickmann A, Löffek S, Livingstone E, Ugurel S, Zimmer L, Gunzer M, Schadendorf D, Totzeck M, Rassaf T.
PMID: 34389849
Eur Heart J. 2021 Aug 14; doi: 10.1093/eurheartj/ehab430. Epub 2021 Aug 14.

AIMS: Cardiac immune-related adverse events (irAEs) from immune checkpoint inhibition (ICI) targeting programmed death 1 (PD1) are of growing concern. Once cardiac irAEs become clinically manifest, fatality rates are high. Cardio-oncology aims to prevent detrimental effects before manifestation of...

Cite
Michel L, Helfrich I, Hendgen-Cotta UB, et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2021;doi: 10.1093/eurheartj/ehab430.
Michel, L., Helfrich, I., Hendgen-Cotta, U. B., Mincu, R. I., Korste, S., Mrotzek, S. M., Spomer, A., Odersky, A., Rischpler, C., Herrmann, K., Umutlu, L., Coman, C., Ahrends, R., Sickmann, A., Löffek, S., Livingstone, E., Ugurel, S., Zimmer, L., Gunzer, M., Schadendorf, D., Totzeck, M., & Rassaf, T. (2021). Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. European heart journal, . https://doi.org/10.1093/eurheartj/ehab430
Michel, Lars, et al. "Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy." European heart journal vol. (2021). doi: https://doi.org/10.1093/eurheartj/ehab430
Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, Spomer A, Odersky A, Rischpler C, Herrmann K, Umutlu L, Coman C, Ahrends R, Sickmann A, Löffek S, Livingstone E, Ugurel S, Zimmer L, Gunzer M, Schadendorf D, Totzeck M, Rassaf T. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2021 Aug 14; doi: 10.1093/eurheartj/ehab430. Epub 2021 Aug 14. PMID: 34389849.
Copy Download .nbib Format: NLM
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.

European journal of cancer (Oxford, England : 1990)

Weber JS, Ascierto PA, Middleton MR, Hennicken D, Zoffoli R, Pieters A, Amadi A, Kupas K, Kotapati S, Moshyk A, Schadendorf D.
PMID: 34663559
Eur J Cancer. 2021 Nov;158:225-233. doi: 10.1016/j.ejca.2021.08.028. Epub 2021 Oct 15.

BACKGROUND: Nivolumab (an anti-programmed death-1 antibody) is an adjuvant standard of care for patients with high-risk resected melanoma, although a watch-and-wait strategy remains an option. In the absence of head-to-head evidence, an indirect treatment comparison (ITC) of adjuvant nivolumab...

Cite
Weber JS, Ascierto PA, Middleton MR, et al. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. Eur J Cancer. 2021;158:225-233doi: 10.1016/j.ejca.2021.08.028.
Weber, J. S., Ascierto, P. A., Middleton, M. R., Hennicken, D., Zoffoli, R., Pieters, A., Amadi, A., Kupas, K., Kotapati, S., Moshyk, A., & Schadendorf, D. (2021). Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. European journal of cancer (Oxford, England : 1990), 158225-233. https://doi.org/10.1016/j.ejca.2021.08.028
Weber, Jeffrey S, et al. "Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma." European journal of cancer (Oxford, England : 1990) vol. 158 (2021): 225-233. doi: https://doi.org/10.1016/j.ejca.2021.08.028
Weber JS, Ascierto PA, Middleton MR, Hennicken D, Zoffoli R, Pieters A, Amadi A, Kupas K, Kotapati S, Moshyk A, Schadendorf D. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. Eur J Cancer. 2021 Nov;158:225-233. doi: 10.1016/j.ejca.2021.08.028. Epub 2021 Oct 15. PMID: 34663559.
Copy Download .nbib Format: NLM
SIRT1-mediated deacetylation of FOXO3a transcription factor supports pro-angiogenic activity of interferon-deficient tumor-associated neutrophils.

International journal of cancer

Bordbari S, Mörchen B, Pylaeva E, Siakaeva E, Spyra I, Domnich M, Droege F, Kanaan O, Lang KS, Schadendorf D, Lang S, Helfrich I, Jablonska J.
PMID: 34751438
Int J Cancer. 2021 Nov 09; doi: 10.1002/ijc.33871. Epub 2021 Nov 09.

Angiogenesis plays an important role during tumor growth and metastasis. We could previously show that Type I interferon (IFN)-deficient tumor-associated neutrophils (TANs) show strong pro-angiogenic activity, and stimulate tumor angiogenesis and growth. However, the exact mechanism responsible for their...

Cite
Bordbari S, Mörchen B, Pylaeva E, et al. SIRT1-mediated deacetylation of FOXO3a transcription factor supports pro-angiogenic activity of interferon-deficient tumor-associated neutrophils. Int J Cancer. 2021;doi: 10.1002/ijc.33871.
Bordbari, S., Mörchen, B., Pylaeva, E., Siakaeva, E., Spyra, I., Domnich, M., Droege, F., Kanaan, O., Lang, K. S., Schadendorf, D., Lang, S., Helfrich, I., & Jablonska, J. (2021). SIRT1-mediated deacetylation of FOXO3a transcription factor supports pro-angiogenic activity of interferon-deficient tumor-associated neutrophils. International journal of cancer, . https://doi.org/10.1002/ijc.33871
Bordbari, Sharareh, et al. "SIRT1-mediated deacetylation of FOXO3a transcription factor supports pro-angiogenic activity of interferon-deficient tumor-associated neutrophils." International journal of cancer vol. (2021). doi: https://doi.org/10.1002/ijc.33871
Bordbari S, Mörchen B, Pylaeva E, Siakaeva E, Spyra I, Domnich M, Droege F, Kanaan O, Lang KS, Schadendorf D, Lang S, Helfrich I, Jablonska J. SIRT1-mediated deacetylation of FOXO3a transcription factor supports pro-angiogenic activity of interferon-deficient tumor-associated neutrophils. Int J Cancer. 2021 Nov 09; doi: 10.1002/ijc.33871. Epub 2021 Nov 09. PMID: 34751438.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 129 entries